title: [Is a non-invasive management allowed for maternofetal alloimmune thrombocytopenia? Experience over a 10-year period].
abstract: OBJECTIVE
  Our purpose was to study a non-invasive management of fetomaternal alloimmune thrombocytopenia (FMAIT).
  
  
  METHODS
  Between 1996 and 2005, 18 women were treated. The population was divided into 2 groups: patients with a history of intracranial haemorrhage (ICH) in the older sibling received weekly intravenous immunoglobulin (IVIG) therapy to the mother (1 g/kg per week) without initial cordocentesis whereas patients with a history of neonatal thrombocytopenia did not undergo any treatment.
  
  
  RESULTS
  All pregnancies with a previous FMAIT were monitored with serial ultrasound scans without cordecentesis. 15 patients had HPA-1, 2 HPA-3 and 1 HPA-5 immunizations. Weekly intravenous immunoglobulin therapy was administered in 5 patients with a history of ICH in the older sibling. Two of these delivered thrombocytopenic children; one had a platelet count < 50 x 10(9)/l. For the 13 women (one twin) who had a sibling with neonatal thrombocytopenia, 11/14 newborns had a platelet count < 50 x 10(9)/l. Predelivery fetal blood sampling were performed in 8/18 pregnancies. The neonatal periods of the 19 children were uncomplicated and no ICHs were observed.
  
  
  CONCLUSIONS
  Our results suggest that a non-invasive strategy avoiding serial cordocentesis may be an effective therapy in patients who are at risk of fetal and neonatal alloimmune thrombocytopenia.
authors.affiliation: Clinique de Gynécologie, d'Obstétrique et de Néonatologie, Hôpital Jeanne-de-Flandre, Centre Hospitalier Régional Universitaire (CHRU) de Lille, 1, rue Eugène-Avinée, 59037 Lille cedex, France. p-deruelle@chru-lille.fr
authors.forename: P
authors.initials: P
authors.lastname: Deruelle
authors.forename: B
authors.initials: B
authors.lastname: Wibaut
authors.forename: L
authors.initials: L
authors.lastname: Manessier
authors.forename: D
authors.initials: D
authors.lastname: Subtil
authors.forename: P
authors.initials: P
authors.lastname: Vaast
authors.forename: F
authors.initials: F
authors.lastname: Puech
authors.forename: A-S
authors.initials: AS
authors.lastname: Valat
mesh_terms: D000328:Adult; D017218:Cordocentesis; D005260:Female; D005312:Fetal Blood / Q000166:cytology; D005315:Fetal Diseases / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007231:Infant, Newborn; D020300:Intracranial Hemorrhages / Q000209:etiology / Q000517:prevention & control; D008297:Male; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D011256:Pregnancy Outcome; D012307:Risk Factors; D013921:Thrombocytopenia / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous